Restoring implant fixation strength in osteoporotic bone with a hydrogel locally delivering zoledronic acid and bone morphogenetic protein 2. A longitudinal in vivo microCT study in rats.

Bone morphogenetic protein 2 Hydrogel Implant fixation In vivo microCT Osseointegration Osteoporosis Rat Zoledronic acid

Journal

Bone
ISSN: 1873-2763
Titre abrégé: Bone
Pays: United States
ID NLM: 8504048

Informations de publication

Date de publication:
02 Jan 2024
Historique:
received: 23 10 2023
revised: 27 12 2023
accepted: 28 12 2023
medline: 5 1 2024
pubmed: 5 1 2024
entrez: 4 1 2024
Statut: aheadofprint

Résumé

Osteoporosis poses a major public health challenge, and it is characterized by low bone mass, deterioration of the microarchitecture of bone tissue, causing a consequent increase in bone fragility and susceptibility to fractures and complicating bone fixation, particularly screw implantation. In the present study, our aim was to improve implant stability in osteoporotic bone using a thermoresponsive hyaluronan hydrogel (HA-pNIPAM) to locally deliver the bisphosphonate zoledronic acid (ZOL) to prevent bone resorption and bone morphogenetic protein 2 (BMP2) to induce bone formation. Adult female Wistar rats (n = 36) were divided into 2 treatment groups: one group of SHAM-operated animals and another group that received an ovariectomy (OVX) to induce an osteoporotic state. All animals received a polyetheretherketone (PEEK) screw in the proximal tibia. In addition, subgroups of SHAM or OVX animals received either the HA-pNIPAM hydrogel without or with ZOL/BMP2, placed into the defect site prior to screw implantation. Periprosthetic bone and implant fixation were monitored using longitudinal in vivo microCT scanning post-operatively and at 3, 6, 9, 14, 20 and 28 days. Histological assessment was performed post-mortem. Our data showed that pure hydrogel has no impact of implant fixation The ZOL/BMP2-hydrogel significantly increased bone-implant contact and peri-implant bone fraction, primarily through reduced resorption. STATEMENT OF CLINICAL SIGNIFICANCE: Local delivery of ZOL and BMP2 using a biocompatible hydrogel improved implant stability in osteoporotic bone. This approach could constitute a potent alternative to systemic drug administration and may be useful in avoiding implant loosening in clinical settings.

Identifiants

pubmed: 38176642
pii: S8756-3282(23)00344-7
doi: 10.1016/j.bone.2023.117011
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

117011

Informations de copyright

Copyright © 2023. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors are not compensated, and no other institutional subsidies, corporate affiliations, or funding sources support this work unless clearly documented and disclosed. No external funds were received in support of this work.

Auteurs

Claudia Siverino (C)

AO Research Institute Davos, Davos, Switzerland.

Laura Kyllönen (L)

AO Research Institute Davos, Davos, Switzerland.

Linda Freitag (L)

AO Research Institute Davos, Davos, Switzerland.

Christian Günther (C)

AO Research Institute Davos, Davos, Switzerland.

Keith Thompson (K)

AO Research Institute Davos, Davos, Switzerland.

Ursula Styger (U)

AO Research Institute Davos, Davos, Switzerland.

Stephan Zeiter (S)

AO Research Institute Davos, Davos, Switzerland.

David Eglin (D)

AO Research Institute Davos, Davos, Switzerland; Mines Saint-Étienne, Univ Jean Monnet, INSERM, U1059 Sainbiose, Saint-Étienne F, France.

Vincent A Stadelmann (VA)

AO Research Institute Davos, Davos, Switzerland; Schulthess Klinik, Department of Research and Development, Zürich, Switzerland. Electronic address: vincent.stadelmann@kws.ch.

Classifications MeSH